Prognostic value of genomic damage in non-small-cell lung cancer
1998

Genomic Damage in Non-Small-Cell Lung Cancer

Sample size: 65 publication Evidence: moderate

Author Information

Author(s): C de Juan, P Iniestal, FJ Vega, MA Peinado, C Fernandez, T Caldes, M Jose Massa, JA López, A Sanchez, AJ Torres, JL Balibrea, M Benito

Primary Institution: Universidad Complutense, Madrid, Spain

Hypothesis

Does genomic damage affect patient survival in non-small-cell lung cancer?

Conclusion

High genomic damage in non-small-cell lung cancer patients is associated with poorer prognosis.

Supporting Evidence

  • Patients with high genomic damage showed a poorer prognosis than those with low or moderate genomic damage.
  • Multivariate analysis indicated that high genomic damage was associated with a risk ratio 4.26 times higher than other patients.
  • 64% of genomic changes detected were gains in genomic sequences.

Takeaway

This study found that patients with more genomic damage in their lung cancer have a worse chance of survival.

Methodology

Genomic alterations were analyzed in 65 non-small-cell lung cancer tissue samples using arbitrarily primed polymerase chain reaction (AP-PCR).

Limitations

The study only included patients with stages I, II, and IIIA tumors, excluding those with more advanced stages.

Participant Demographics

64 men and 1 woman, median age 62.2 years.

Statistical Information

P-Value

0.038

Confidence Interval

95% CI = 1.03-17.54

Statistical Significance

p=0.038

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication